| N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells JK Lee, JW Phillips, BA Smith, JW Park, T Stoyanova, EF McCaffrey, ... Cancer cell 29 (4), 536-547, 2016 | 356 | 2016 |
| Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage JW Park, JK Lee, KM Sheu, L Wang, NG Balanis, K Nguyen, BA Smith, ... Science 362 (6410), 91-95, 2018 | 247 | 2018 |
| The role of lineage plasticity in prostate cancer therapy resistance H Beltran, A Hruszkewycz, HI Scher, J Hildesheim, J Isaacs, EY Yu, ... Clinical cancer research 25 (23), 6916-6924, 2019 | 238 | 2019 |
| Phosphoproteome integration reveals patient-specific networks in prostate cancer JM Drake, EO Paull, NA Graham, JK Lee, BA Smith, B Titz, T Stoyanova, ... Cell 166 (4), 1041-1054, 2016 | 220 | 2016 |
| Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay JW Park, JK Lee, JW Phillips, P Huang, D Cheng, J Huang, ON Witte Proceedings of the National Academy of Sciences 113 (16), 4482-4487, 2016 | 142 | 2016 |
| Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets JM Drake, NA Graham, JK Lee, T Stoyanova, CM Faltermeier, S Sud, ... Proceedings of the National Academy of Sciences 110 (49), E4762-E4769, 2013 | 128 | 2013 |
| Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer JM Drake, JK Lee, ON Witte Molecular and cellular biology, 2014 | 116 | 2014 |
| Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer JK Lee, NJ Bangayan, T Chai, BA Smith, TE Pariva, S Yun, A Vashisht, ... Proceedings of the National Academy of Sciences 115 (19), E4473-E4482, 2018 | 106 | 2018 |
| FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate JW Park, JK Lee, ON Witte, J Huang Modern Pathology 30 (9), 1262-1272, 2017 | 93 | 2017 |
| Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer Y Li, Y He, W Butler, L Xu, Y Chang, K Lei, H Zhang, Y Zhou, AC Gao, ... Science translational medicine 11 (521), eaax0428, 2019 | 66 | 2019 |
| Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer T Stoyanova, M Riedinger, S Lin, CM Faltermeier, BA Smith, KX Zhang, ... Proceedings of the National Academy of Sciences 113 (42), E6457-E6466, 2016 | 54 | 2016 |
| Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer DC DeLucia, TM Cardillo, L Ang, MP Labrecque, A Zhang, JE Hopkins, ... Clinical Cancer Research 27 (3), 759-774, 2021 | 44 | 2021 |
| Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy BR Winters, N De Sarkar, S Arora, H Bolouri, S Jana, F Vakar-Lopez, ... JCI insight 4 (13), 2019 | 38 | 2019 |
| Targeting RET kinase in neuroendocrine prostate cancer HR VanDeusen, JR Ramroop, KL Morel, SY Bae, AV Sheahan, Z Sychev, ... Molecular Cancer Research 18 (8), 1176-1188, 2020 | 36 | 2020 |
| Identification of therapeutic vulnerabilities in small-cell neuroendocrine prostate cancer AN Corella, MVA Cabiliza Ordonio, I Coleman, JM Lucas, A Kaipainen, ... Clinical Cancer Research 26 (7), 1667-1677, 2020 | 31 | 2020 |
| Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer A Vichas, AK Riley, NT Nkinsi, S Kamlapurkar, PCR Parrish, A Lo, F Duke, ... Nature communications 12 (1), 4789, 2021 | 27 | 2021 |
| De novo induction of lineage plasticity from human prostate luminal epithelial cells by activated AKT1 and c-Myc OJ Kwon, L Zhang, D Jia, Z Zhou, Z Li, M Haffner, JK Lee, L True, ... Oncogene 39 (48), 7142-7151, 2020 | 27 | 2020 |
| Shared Antigen-specific CD8+ T cell Responses Against the SARS-COV-2 Spike Protein in HLA-A*02:01 COVID-19 Participants W Chour, AM Xu, AHC Ng, J Choi, J Xie, D Yuan, DC DeLucia, ... MedRxiv, 2020.05. 04.20085779, 2020 | 27 | 2020 |
| Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes LN Diamantopoulos, AR Khaki, P Grivas, JL Gore, GR Schade, AC Hsieh, ... Bladder Cancer 6 (1), 71-81, 2020 | 24 | 2020 |
| Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy V Bhatia, NV Kamat, TE Pariva, LT Wu, A Tsao, K Sasaki, H Sun, G Javier, ... Nature Communications 14 (1), 2041, 2023 | 21 | 2023 |
